G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023

Feb 2023| TBR1171D| TBRC (Publisher)

Sample Report

Report Highlights

Including: 1) By Type: Lenograstim (Granocyte); Filgrastim (Neupogen, Zarzio, Nivestim, Accofil); Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco); Lipegfilgrastim (Lonquex)
2) By Application: Oncological Diseases; Blood Disorders; Growth Hormone Deficiencies; Chronic And Autoimmune Disorders
3) By Product: Tablet; Capsule
Covering: BioCad; Teva Pharmaceuticals; Pfizer; Intas Pharmaceuticals; Novartis AG

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2023 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on g-csf (granulocyte colony stimulating factors) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia – Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Description:
Where is the largest and fastest growing market for g-csf (granulocyte colony stimulating factors) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The g-csf (granulocyte colony stimulating factors) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Report Synopsis

Report Metrics	Details
Base year considered	2022
Forecast period considered	2022-2032
Units considered	$ Billion
Segments covered	By Type, By Application, By Product
Industry covered	Pharmaceuticals
Regions covered	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Countries covered	Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA
Companies studied	BioCad Dr. Reddy's Laboratories Teva Pharmaceuticals Pfizer Intas Pharmaceuticals Novartis AG Stada Arzneimittel Dong-A Socio Group Amgen Celltrion Inc. Emcure Pharmaceuticals

Scope

Markets Covered:

By Type: Lenograstim (Granocyte); Filgrastim (Neupogen, Zarzio, Nivestim, Accofil); Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco); Lipegfilgrastim (Lonquex)
By Application: Oncological Diseases; Blood Disorders; Growth Hormone Deficiencies; Chronic And Autoimmune Disorders; Other Applications
By Product: Tablet; Capsule; Other Products

Companies Mentioned: BioCad; Teva Pharmaceuticals; Pfizer; Intas Pharmaceuticals; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Table 1 : Global Historic Market Growth, 2017-2022, $ Billion
Table 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 6 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 7 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 8 : Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 9 : Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 10 : China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 11 : China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 12 : India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 13 : India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 14 : Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 15 : Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 16 : Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 17 : Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 18 : Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 19 : Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 20 : South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 21 : South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 22 : Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 23 : Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 24 : UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 25 : UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 26 : Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 27 : Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 28 : France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 29 : France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 30 : Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 31 : Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 32 : Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 33 : Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 34 : North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 35 : North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 36 : USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 37 : USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 38 : South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 39 : South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 40 : Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 41 : Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 42 : Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 43 : Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 44 : Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 45 : Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 46 : BioCad Financial Performance
Table 47 : Teva Pharmaceuticals Financial Performance
Table 48 : Pfizer Financial Performance
Table 49 : Intas Pharmaceuticals Financial Performance
Table 50 : Novartis AG Financial Performance

Figure 1 : Global Historic Market Growth, 2017-2022, $ Billion
Figure 2 : Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Figure 3 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 4 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 5 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Product, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 6 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 7 : Global G-CSF (Granulocyte Colony Stimutating Factors) Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 8 : Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 9 : Asia-Pacific, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 10 : China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 11 : China, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 12 : India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 13 : India, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 14 : Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 15 : Japan, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 16 : Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 17 : Australia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 18 : Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 19 : Indonesia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 20 : South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 21 : South Korea, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 22 : Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 23 : Western Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 24 : UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 25 : UK, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 26 : Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 27 : Germany, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 28 : France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 29 : France, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 30 : Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 31 : Eastern Europe, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 32 : Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 33 : Russia, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 34 : North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 35 : North America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 36 : USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 37 : USA, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 38 : South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 39 : South America, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 40 : Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 41 : Brazil, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 42 : Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 43 : Middle East, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 44 : Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 45 : Africa, G-CSF (Granulocyte Colony Stimutating Factors) Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Figure 46 : BioCad Financial Performance
Figure 47 : Teva Pharmaceuticals Financial Performance
Figure 48 : Pfizer Financial Performance
Figure 49 : Intas Pharmaceuticals Financial Performance
Figure 50 : Novartis AG Financial Performance

The Business Research Company is a market research and intelligence company which excels in company, market and consumer research. It has over 50 research professionals at its offices in India, the UK and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Similar Reports from TBRC (Publisher)

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Report 2022

Published Date - Mar 2022
Report Code - TBR1171C

Including: 1) By Type: Lenograstim (Granocyte); Filgrastim (Neupogen, Zarzio, Nivestim, Accofil); Long Acting (Pegylated) Filgrastim (Pegfilgrastim, Neulasta, Pelmeg, Ziextenco); Lipegfilgrastim (Lonquex)
2) By Application: Oncological Diseases; Blood Disorders; Growth Hormone Deficiencies; Chronic And Autoimmune Disorders; Others
3) By Product: Tablet; Capsule; Others
Covering: BioCad; Teva Pharmaceuticals; Pfizer; Intas Pharmaceuticals; Novartis AG; Stada Arzneimittel; Dong-A Socio Group

G-CSF (Granulocyte ...

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

Published Date - Mar 2021
Report Code - TBR1171B

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Opportunities And Strategies To 2030: COVID-19 Growth and Change

Including: 1) By Type: Pegfilgrastim; Filgrastim; Lenograstim; Others
2) By Application: Oncology; Blood Disorders; Chronic and Autoimmune Disorders; Others

Covering: Amgen Inc.; Coherus Biosciences Inc.; Sandoz (Novartis); Biocon/Mylan; Teva Pharmaceuticals

G-CSF (Granulocyte Colony Stimulating Factors) Global Market Opportunities And Strategies To 2030: COVID -19 ...

G-CSF (Granulocyte Colony Stimutating Factors) Global Market Report 2020-30: COVID-19 Growth and Change

Published Date - Dec 2020
Report Code - TBR1171A

Including: 1) By Type: Lenograstim (Granocyte); Filgrastim (Neupogen, Zarzio, Nivestim, Accofil); Long acting (pegylated) filgrastim (pegfilgrastim, Neulasta, Pelmeg, Ziextenco); Lipegfilgrastim (Lonquex)

2) By Application: Oncological Diseases; Blood Disorders; Growth Hormone Deficiencies; Chronic and Autoimmune Disorders; Others

Covering: BioCad; Teva Pharmaceuticals; Pfizer; Intas Pharmaceuticals; Novartis AG

G-CSF (Granolocyte Colony Stimutating Factors) Global Market Report 2020-30: Covid 19 Growth And Change from ...